Management of patients with chronic cerebrovascular pathology against the background of metabolic syndrome and diabetes mellitus
- 00:00:05
Introduction: Chronic cerebrovascular diseases and metabolic syndrome – relevance of the problem
- 00:01:26
Metabolic syndrome: pathogenesis and risk factors
- 00:07:27
Obesity and Brain Damage
- 00:13:22
Endothelial dysfunction and chronic cerebral ischemia
- 00:42:06
Mexidol: Efficacy Data for Cognitive Impairments
Ekusheva Evgeniya Viktorovna - Doctor of Medical Sciences, Professor, Head of the Department of Nervous Diseases and Neurorehabilitation of the Academy of Postgraduate Education of the Federal State Budgetary Institution Federal Scientific and Clinical Center of the Federal Medical and Biological Agency of Russia
Shishkova Veronika Nikolaevna - MD, Professor of the Department of Outpatient Therapy of the Faculty of Advanced Medical Studies, State Budgetary Healthcare Institution of the Moscow Region, Moscow Regional Scientific Research Institute named after M.F. Vladimirsky, Professor of the Department of Neuro- and Pathopsychology of the Institute of Psychology named after L.S. Vygotsky, Federal State Budgetary Educational Institution of Higher Education, Russian State University for the Humanities
Announcement:
Chronic cerebrovascular diseases, especially against the background of metabolic syndrome and diabetes mellitus, are one of the key problems of modern medicine. In this video, leading specialists Evgeniya Viktorovna Yekusheva and Veronika Nikolaevna Shishkova analyze pathogenesis, diagnostics and modern approaches to therapy, paying special attention to the role of obesity, insulin resistance and cognitive impairment.
Main topics:
- Relevance of the problem: metabolic syndrome (obesity, hypertension, diabetes) is a key risk factor for chronic brain damage. Every fourth person in developed countries suffers from it, and forecasts indicate a 50% increase in cases in the next 20 years.
- Pathogenesis: Systemic inflammation, insulin resistance and endothelial dysfunction lead to microangiopathy, lacunar infarctions and cognitive impairment. Neurological disorders are detected in 95% of obese patients.
- The role of obesity: abdominal obesity is a risk marker even with a normal BMI. An increase in waist circumference by 1 cm increases the likelihood of cardiovascular complications.
- Cognitive impairment: the tip of the iceberg of cerebrovascular pathology. Manifested by a decrease in memory, executive functions and psychomotor speed, but often remains underestimated.
- Therapy:
- Non-pharmacological methods: physical activity and lifestyle modification are critical.
- Pharmacological support: Mexidol is a drug with proven effectiveness in improving cognitive functions, reducing insulin resistance and normalizing the lipid profile. Consistent therapy with the drug demonstrates stable positive effects.
Key findings:
- Early diagnosis of metabolic disorders and cognitive deficits can slow the progression of diseases.
- An integrated approach (correction of risk factors + drug therapy) is the gold standard for patient care.
For whom: neurologists, therapists, cardiologists, endocrinologists and doctors of related specialties.
- 00:00:05
Introduction: Chronic cerebrovascular diseases and metabolic syndrome – relevance of the problem
- 00:01:26
Metabolic syndrome: pathogenesis and risk factors
- 00:07:27
Obesity and Brain Damage
- 00:13:22
Endothelial dysfunction and chronic cerebral ischemia
- 00:42:06
Mexidol: Efficacy Data for Cognitive Impairments